BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Contract Services Contract Manufacturing

Samsung Biologics Accelerates Sustainability Strategy with Stronger ESG Performance

Advanced environmental performance through renewable energy transition and enhanced carbon transparency Strengthened sustainability management and suppl...

July 01, 2026 | News

Lonza Expands Commercial ADC Payload-Linker Manufacturing at Visp to Support Growing Oncology Pipeline

Lonza to expand payload-linker manufacturing capacity in Visp (CH) to support the rapidly growing antibody-drug conjugate (ADC) market Investment...

July 01, 2026 | News

Innovent and Lilly Expand China Oncology Partnership with Verzenios Commercialisation Agreement

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality m...

July 01, 2026 | News

Icosagen Completes €45 Million Expansion to Deliver End-to-End Biologics Development and GMP Manufacturing at a Single Site

Estonia-based biotechnology company Icosagen has completed a major strategic expansion to strengthen its integrated biologics development and man...

July 01, 2026 | News

C-Ray Therapeutics Secures Radiopharmaceutical Production Licence, Strengthening CRDMO Capabilities in China

C-Ray Therapeutics (Chengdu) Co., Ltd. ("C-Ray Therapeutics") completed on-site inspections conducted by a panel of experts from the Sichuan Provincial Cen...

June 25, 2026 | News

Vendor to Co-Innovator — or Bring It In-House? The CDMO Relationship Rewires

For two decades the contract development and manufacturing organisation occupied a comfortable, clearly understood place in the biopharma value chain. The ...

June 25, 2026 | Analysis

WuXi Biologics Achieves First GMP Production at Shanghai MFG17, Expanding Global Biologics Manufacturing Capacity

WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that its MFG17 drug substance f...

June 25, 2026 | News

Chime Biologics Expands Manufacturing Capacity With New GMP-2 Facility And AI Powered Megafactory Vision

Chime Biologics’ manufacturing expansion builds on a decade of collaboration enabled by Cytiva’s modular manufacturing platform ...

June 10, 2026 | News

WuXi Biologics Completes Topping Out of Singapore Drug Product Facility

WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has completed the toppi...

June 08, 2026 | News

WuXi Vaccines Secures Second ANVISA GMP Certification To Accelerate Brazil Dengue Vaccine Manufacturing

WuXi Vaccines, a wholly-owned subsidiary of WuXi Biologics, dedicated to vaccine Contract Development and Manufacturing Organization (CDMO), announced that...

May 27, 2026 | News

Curocell And ProBio Achieve Korean Milestone With Approval Of Next Generation CAR T Therapy Anbal cel

Next-generation anti-CD19 CAR-T, Anbal-cel (CRC01), approval highlights Korean innovation Given the accelerating global momentum in CAR-T and gene th...

May 13, 2026 | News

VectorBuilder Secures European Patent For MiniVec Plasmid System Advancing Genetic Medicine Development

Small by design, built for the demands of modern genetic medicine across gene therapy, cell therapy, and vaccines VectorBuilder, a global leader in ...

May 06, 2026 | News

WuXi Biologics Advances Global Sustainability Strategy With 2025 ESG Report

Contributing to the United Nations Sustainable Development Goals, driving equitable access to healthcare through technology and innovation Enhancing gov...

May 01, 2026 | News

Samsung Bioepis Co., Ltd. And ATLATL Innovation Center Forge APAC Open Innovation Pact To Accelerate Early Stage Biotech Growth

Samsung Bioepis Co., Ltd. and ATLATL Innovation Center (hereinafter referred to as "ATLATL"), global innovation platform for life science research and deve...

April 29, 2026 | News

Stay Connected